

Gastrointestinal (GI) Disease-Oriented Team

Clinical Research Treatment Trial Flowchart



NEOADJUVANT

CCTG-CO32
(NEO-RT trial)

(opened 4/29/24)
Coord: P. Yang

PI: Dr. Zell
Accrual: 3/5

ADJUVANT

NRG-GI008/CIRCULATE
(ctDNA guided tx)

(opened 9/14/22)
Coord: A. Ballard

PI: Dr. Zell
Accrual: 5/10

INTRA-OPERATIVE

UCI 24-103
(Y90 Resin Spheres vs
SOC of mCRC liver metastases)

Coord: TBD
PI: Dr. Abi-Jaoudeh
Pending activation

MOLECULAR FAILURE

UCI 20-43
(TAS102 + irinotecan)

(opened 5/24/22)
Coord: A. Ballard

PI: Dr. Dayyani
Accrual: 14/17



1L METASTATIC

A022101

(at least 4 months of chemo once metastatic disease is confirmed)

Coord: A. Ballard

PI: Dr. Eng
Accrual: 1/2

UCI 25-155

(Ivonescimab + FOLFOX vs Bevacizumab + FOLFOX)

(opened 2/26/26)

Coord: P. Yang
PI: Dr. Dayyani
Accrual 3/15

UCI 25-196

(Pumitamig + Chemo vs Bevacizumab + Chemo)

(opened 4/6/26)

Coord: N. Ferrand
PI: Dr. Dayyani
Accrual 0/5

2L METASTATIC

ETCTN 10670

(Abemaciclib + 5-Fluorouracil)

(opened 4/8/25)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 5/8

UCI 23-85

(BA3182 + (EPCAM)/CD3 Antibody)

(opened 9/19/24)

Coord: P. Yang

PI: Dr. Valerin
Accrual: 8/18

ETCTN 10605

(ZEN-3694 + Cetuximab and Encorafenib; BRAF V600E)

(opened 1/14/26)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 0/3

3L METASTATIC

UCI 24-142

(VET3-TGI +/- pembrolizumab)

(opened 3/7/25)

Coord: N. Ferrand

PI: Dr. Uchio
Accrual: 2/4

UCI 24-93

(Fruquintinib)

(opened 5/28/25)

Coord: N. Ferrand

PI: Dr. Dayyani
Accrual: 5/14

UCI 25-149

(Metformin use for Pseudomyxoma
Peritonei secondary to appendiceal
mucinous neoplasms)

Coord: C. Jonsson

PI: Dr. Eng
Pending activation

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Newly Diagnosed

Advanced/Metastatic

Neoadjuvant

UCI 21-191
 (SOC w/ ctDNA testing)
(opened 6/27/25)
 Coord: A. Ballard

PI: Dr. Dayyani
 Accrual: 12/20

UCI 23-184
 (Pafolacianine for Imaging of
 Peritoneal Carcinomatosis)

Coord: L. Mejia
 PI: Dr. Senthil
 Accrual: 8/10

ESCC

UCI 24-77
 (I-DXd)
(opened 2/5/26)
 Coord: C. Jonsson

PI: Dr. Dayyani
 Accrual: 0/5

Newly Diagnosed Metastatic

A022102
 (mFOLFIRINOX +/-
 Nivolumab vs. FOLFOX +/-
 Nivolumab)

Coord: C. Jonsson
 PI: Dr. Dayyani
 Accrual: 9/14

UCI 21-10
 (FOLFOX + nivo + TJ033721
 (anti-CLDN18.2 + anti-4-1BB))

Coord: M. Nguyen; C.
 Jonsson
 PI: Dr. Dayyani
 Accrual: 34/50

EA2234
 (IP/IV Paclitaxel + IV 5-FU +
 LV VS SOC)
(opened 8/28/25)

Coord: L. Mejia
 PI: Dr. Senthil
 Accrual: 10/65

UCI 25-203
 (Pumitamig + Chemo vs.
 Nivolumab + Chemo)

Coord: N. Ferrand
 PI: Dr. Dayyani
Pending activation

Recurrent

UCI 16-94
 (Tirapazamine, Nivolumab)

(opened 6/15/23)
 Coord: M Duron
 PI: Dr. Abi-Jaoudeh
 Accrual: 36/48

UCI 24-49
 (Beamion BCGC-1:
 Oral Zongertinib + Trastuzumab
 Deruxtecan or + Trastuzumab
 Emtansine)
(opened 10/22/24)

Coord: M. Nguyen
 PI: Dr. Dayyani
 Accrual: 3/10

UCI 23-173
 (ICI in ARID1a Mu)

Coord: TBD
 PI: Dr. Dayyani
Pending activation

HER-2

ETCTN-10495
(DS8201a + Neratinib)
(opened 3/5/25)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 2/7

UCI 24-49
(Beamion BCGC-1:
Oral Zongertinib +
Trastuzumab Deruxtecan)
(opened 10/22/24)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 3/10

KRAS

UCI 25-163
(BBO-11818)

Coord: K. Buttigieg

PI: Dr. Arter
Pending activation

Open to Accrual

EGFR

Low Accruing

CLDN18.2

UCI 21-10
(FOLFOX + nivo +
TJ033721 (anti-CLDN
18.2 + anti-4-1BB)

Coord: M. Nguyen

PI: Dr. Dayyani
Accrual: 34/50

Pending Activation/Suspended



Advanced Solid Tumor

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 23-85
(BA3182 + (EPCAM)/CD3 Antibody)

(opened 9/19/24)

Coord: P. Yang
PI: Dr. Valerin
Accrual: 8/18

UCI 22-26
(Androgen and glucocorticoid receptor antagonist)

Coord: B. Nguyen
PI: Dr. Dayyani
Accrual: 11/12

ETCTN-10579
(ZEN003694 (ZEN-3694) + capecitabine)

(opened 10/27/23)

Coord: P. Yang
PI: Dr. FC Lee
Accrual: 2/4

UCI 21-241
(ALK inhibitor NLV-655)

(opened 10/4/22)

Coord: A. Ballard
PI: Dr. Nagasaka
Accrual: 20/25

UCI 25-16
(ODM-212)

(opened 8/29/2025)

Coord: P. Yang
PI: Dr. Dayyani
Accrual: 8/10

UCI 24-138
(Tarlatab in DLL3 Expressing Tumors + Neuroendocrine Neoplasms)

(opened 10/31/2025)

Coord: N. Ferrand
PI: Dr. Park
Accrual: 2/5

ETCTN-10572
(Temozolomide + M1774)

(opened 12/11/2025)

Coord: M. Nguyen
PI: Dr. Dayyani
Accrual: 1/10

UCI 24-113
(BMS-986482 +/- immunotherapy)

(opened 9/29/2025)

Coord: L. Mejia
PI: Dr. Chow
Accrual: 5/10

UCI 24-142
(IV/iTu VET3-TGI +/- atezolizumab)

(opened 3/7/2025)

Coord: N. Ferrand
PI: Dr. Uchio
Accrual: 2/4

UCI 25-75
(CRN09682- on SST2 expressing tumors)

(opened 2/18/2026)

Coord: S. Duong
PI: Dr. Dayyani
Accrual: 0/15

UCI 25-190 (STOPGAP-B)
(IP Paclitaxel + SOC in GI Malignancies with Peritoneal Carcinomatosis)

Coord: TBD

PI: Dr. Senthil
Pending activation



■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

UCI 03-03
(Immunologic response analysis)

Coord: B. Sanchez
PI: Dr. Imagawa
Accrual: 336/400

(ID GenomeSig for HomoRecomboDeficiency inPC &Mismatch RepairDeficiency in Microsatellite Instable CC)
(opened 3/13/2025)
PI: Dr. Pannunzio/Dr. Valerin
Accrual: 16/50

UCI 24-05
(Riluzole for Cancer-related Cognitive Impairment)

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 26/59

UCI 25-48
(Riluzole For Preventing Cognitive Dysfunction in Pts Receiving Chemo (REFOCUS))

Coord: M. Nguyen
PI: Dr. Chan
Accrual: 6/20

Supportive Trials